128 related articles for article (PubMed ID: 8270986)
21. Malignant mixed Müllerian tumors of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 44 cases.
Blom R; Guerrieri C; Stâl O; Malmström H; Sullivan S; Simonsen E
Gynecol Oncol; 1998 Jan; 68(1):18-24. PubMed ID: 9454654
[TBL] [Abstract][Full Text] [Related]
22. [Prognosis value of p53, C-erB-2 and Ki67 proteins in ovarian carcinoma].
Frutuoso C; Silva MR; Amaral N; Martins I; De Oliveira C; De Oliveira HM
Acta Med Port; 2001; 14(3):277-83. PubMed ID: 11552325
[TBL] [Abstract][Full Text] [Related]
23. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
Laframboise S; Chapman W; McLaughlin J; Andrulis IL
Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer.
Baekelandt M; Kristensen GB; Nesland JM; Tropé CG; Holm R
J Clin Oncol; 1999 Jul; 17(7):2061. PubMed ID: 10561259
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of DNA content in epithelial ovarian cancer.
Gajewski WH; Fuller AF; Pastel-Ley C; Flotte TJ; Bell DA
Gynecol Oncol; 1994 Apr; 53(1):5-12. PubMed ID: 8175021
[TBL] [Abstract][Full Text] [Related]
26. p53 accumulation in ovarian carcinomas and its prognostic implications.
Bosari S; Viale G; Radaelli U; Bossi P; Bonoldi E; Coggi G
Hum Pathol; 1993 Nov; 24(11):1175-9. PubMed ID: 8244317
[TBL] [Abstract][Full Text] [Related]
27. Molecular profile of advanced-stage transitional cell carcinoma of the ovary.
Gershenson DM; Baker VV; Price JE; Hung MC; El-Naggar AK; Tortolero-Luna G; Silva EG
Am J Obstet Gynecol; 1997 Jul; 177(1):120-5. PubMed ID: 9240594
[TBL] [Abstract][Full Text] [Related]
28. [Relationship between expressions of p53, c-erbB2 genes, proliferating cell nuclear antigen and prognosis of patients with ovarian epithelial carcinoma].
Li JD; Li MD; Li YF; Huang X; Liu JH; Liu FY; Zhang CQ
Ai Zheng; 2002 Mar; 21(3):292-6. PubMed ID: 12451998
[TBL] [Abstract][Full Text] [Related]
29. p53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer: a multivariate analysis.
Dogan E; Saygili U; Tuna B; Gol M; Gürel D; Acar B; Koyuncuoğlu M
Gynecol Oncol; 2005 Apr; 97(1):46-52. PubMed ID: 15790436
[TBL] [Abstract][Full Text] [Related]
30. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma.
Gilks CB; Ionescu DN; Kalloger SE; Köbel M; Irving J; Clarke B; Santos J; Le N; Moravan V; Swenerton K;
Hum Pathol; 2008 Aug; 39(8):1239-51. PubMed ID: 18602670
[TBL] [Abstract][Full Text] [Related]
31. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
[TBL] [Abstract][Full Text] [Related]
32. c-erbB-2 and p53 expression in fallopian tube carcinoma.
Lacy MQ; Hartmann LC; Keeney GL; Cha SC; Wieand HS; Podratz KC; Roche PC
Cancer; 1995 Jun; 75(12):2891-6. PubMed ID: 7773939
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of DNA quantification in early epithelial ovarian carcinoma.
Valverde JJ; Martin M; García-Asenjo JA; Casado A; Vidart JA; Díaz-Rubio E
Obstet Gynecol; 2001 Mar; 97(3):409-16. PubMed ID: 11239647
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors in ovarian carcinosarcoma: a clinicopathological and immunohistochemical analysis of 23 cases.
Ariyoshi K; Kawauchi S; Kaku T; Nakano H; Tsuneyoshi M
Histopathology; 2000 Nov; 37(5):427-36. PubMed ID: 11119124
[TBL] [Abstract][Full Text] [Related]
35. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical detection of p53 protein in borderline and malignant serous ovarian tumors.
Klemi PJ; Takahashi S; Joensuu H; Kiilholma P; Narimatsu E; Mori M
Int J Gynecol Pathol; 1994 Jul; 13(3):228-33. PubMed ID: 7928055
[TBL] [Abstract][Full Text] [Related]
37. p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer.
Ferrandina G; Fagotti A; Salerno MG; Natali PG; Mottolese M; Maneschi F; De Pasqua A; Benedetti-Panici P; Mancuso S; Scambia G
Br J Cancer; 1999 Oct; 81(4):733-40. PubMed ID: 10574264
[TBL] [Abstract][Full Text] [Related]
38. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma.
Shahin MS; Hughes JH; Sood AK; Buller RE
Cancer; 2000 Nov; 89(9):2006-17. PubMed ID: 11064359
[TBL] [Abstract][Full Text] [Related]
39. [Prognostic value of microvessel density and angiogenesis-related molecules in epithelial ovarian cancer].
Tan XJ; Lang JH; Lou WZ; Shen K; Xu XY
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):274-8. PubMed ID: 18788631
[TBL] [Abstract][Full Text] [Related]
40. Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer.
Isola J; Weitz S; Visakorpi T; Holli K; Shea R; Khabbaz N; Kallioniemi OP
J Clin Oncol; 1993 Jan; 11(1):36-43. PubMed ID: 8093367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
